We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Medicines Co. Offers Update on Dyslipidemia Programs
Read MoreHide Full Article
The Medicines Company came up with important announcements related to its pipeline. The company provided an update on its dyslipidemia programs – MDCO-216 (which contains APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor).
MDCO-216 Misses Early Termination Criteria
The Medicines Co. reported that a planned, interim analysis of the first 40 randomized patients, who completed treatment in the MILANO-PILOT study on MDCO-216, has been reviewed by an Independent Data Monitoring Committee (IDM Committee). Based on the protocol and pre-defined criteria, the IDM Committee recommended the continuation of the MILANO-PILOT study.
The 40-patient data from the MILANO-PILOT study failed to meet the pre-defined, upper statistical boundary efficacy threshold for early termination. Since only a limited number of patients were involved in the first interim analysis, summary data received by the company from the IDM Committee are inconclusive at this moment.
We note that MILANO-PILOT is a proof-of-concept, double-blind, placebo-controlled, randomized study that aims to improve cardiovascular outcomes by reducing plaque burden in patients with atherosclerotic disease. The Medicines Co. has completed enrollment of the planned 120 patients. Data from the study will be presented at the American Heart Association (AHA) Scientific Sessions in Nov 2016.
Concurrently, The Medicines Co. announced that it has completed enrollment in the ORION-1 phase II study on PCSKsi (also known as ALN-PCSsc) ahead of schedule. An interim analysis with a day 90 follow-up for all patients will be conducted and presented at the AHA Scientific Sessions this November. The company anticipates the day 180 follow-up for all patients to be completed, analyzed and presented by the year end.
ORION-1 is a placebo-controlled, double-blind, randomized study that is being conducted on single or multiple subcutaneous injections of PCSK9si in patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (like diabetes and familial hypercholesterolemia) and elevated LDL-C despite maximum tolerated doses of LDL-C lowering therapies.
The Medicines Co. believes that PCSK9si is a first-in-class experimental treatment that acts by turning off PCSK9 synthesis in the liver in contrast to anti-PCSK9 monoclonal antibodies that bind to PCSK9 in blood. Currently, there are two PCSK9 inhibitors available in the market – Amgen Inc.’s (AMGN - Free Report) Repatha and Regeneron Pharmaceuticals, Inc. (REGN - Free Report) /Sanofi’s (SNY - Free Report) Praluent.
The Medicines Co. currently carries a Zacks Rank #3 (Hold). Regeneron is a better-ranked stock in the healthcare sector, with a Zacks Rank #2 (Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
The Medicines Co. Offers Update on Dyslipidemia Programs
The Medicines Company came up with important announcements related to its pipeline. The company provided an update on its dyslipidemia programs – MDCO-216 (which contains APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor).
MDCO-216 Misses Early Termination Criteria
The Medicines Co. reported that a planned, interim analysis of the first 40 randomized patients, who completed treatment in the MILANO-PILOT study on MDCO-216, has been reviewed by an Independent Data Monitoring Committee (IDM Committee). Based on the protocol and pre-defined criteria, the IDM Committee recommended the continuation of the MILANO-PILOT study.
The 40-patient data from the MILANO-PILOT study failed to meet the pre-defined, upper statistical boundary efficacy threshold for early termination. Since only a limited number of patients were involved in the first interim analysis, summary data received by the company from the IDM Committee are inconclusive at this moment.
We note that MILANO-PILOT is a proof-of-concept, double-blind, placebo-controlled, randomized study that aims to improve cardiovascular outcomes by reducing plaque burden in patients with atherosclerotic disease. The Medicines Co. has completed enrollment of the planned 120 patients. Data from the study will be presented at the American Heart Association (AHA) Scientific Sessions in Nov 2016.
MEDICINES CO Price
MEDICINES CO Price | MEDICINES CO Quote
PCSK9 Synthesis Inhibitor Study Fully Enrolled
Concurrently, The Medicines Co. announced that it has completed enrollment in the ORION-1 phase II study on PCSKsi (also known as ALN-PCSsc) ahead of schedule. An interim analysis with a day 90 follow-up for all patients will be conducted and presented at the AHA Scientific Sessions this November. The company anticipates the day 180 follow-up for all patients to be completed, analyzed and presented by the year end.
ORION-1 is a placebo-controlled, double-blind, randomized study that is being conducted on single or multiple subcutaneous injections of PCSK9si in patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (like diabetes and familial hypercholesterolemia) and elevated LDL-C despite maximum tolerated doses of LDL-C lowering therapies.
The Medicines Co. believes that PCSK9si is a first-in-class experimental treatment that acts by turning off PCSK9 synthesis in the liver in contrast to anti-PCSK9 monoclonal antibodies that bind to PCSK9 in blood. Currently, there are two PCSK9 inhibitors available in the market – Amgen Inc.’s (AMGN - Free Report) Repatha and Regeneron Pharmaceuticals, Inc. (REGN - Free Report) /Sanofi’s (SNY - Free Report) Praluent.
The Medicines Co. currently carries a Zacks Rank #3 (Hold). Regeneron is a better-ranked stock in the healthcare sector, with a Zacks Rank #2 (Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>